-
公开(公告)号：US20190338026A1
公开(公告)日：2019-11-07
申请号：US16475223
申请日：2018-01-02
Inventor： X. Charlene LIAO , Qiang LIU , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Chengcheng ZHANG , Mi DENG , Jingjing XIE
Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
-
公开(公告)号：US20210179687A1
公开(公告)日：2021-06-17
申请号：US16762273
申请日：2018-11-06
Inventor： Chengcheng ZHANG , Samuel JOHN , Heyu CHEN , Mi DENG , Xun GUI , Ningyan ZHANG , Zhiqiang AN
IPC: C07K14/705 , A61K45/06 , A61P35/02 , C12N5/0783
Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.
-
公开(公告)号：US20210349096A1
公开(公告)日：2021-11-11
申请号：US16321745
申请日：2017-07-27
Inventor： Chengcheng ZHANG , Zhiqiang AN , Ningyan ZHANG , Mi DENG , Jaehyup KIM , Xun GUI
IPC: G01N33/574 , G01N33/50 , G01N15/14 , G01N21/64
Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.
-
Patent Agency Ranking
公开(公告)号：US20240101667A1
公开(公告)日：2024-03-28
申请号：US18255745
申请日：2021-12-02
Inventor： Chengcheng ZHANG , Guojin WU , Jaehyup KIM , Heyu CHEN , Mi DENG , Zhiqiang AN , Ningyan ZHANG , Ryan HUANG
IPC: C07K16/28 , A61P35/02 , G01N33/574 , G01N33/577
CPC classification number: C07K16/2803 , A61P35/02 , G01N33/574 , G01N33/577 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.
-
公开(公告)号：US20180086829A1
公开(公告)日：2018-03-29
申请号：US15696972
申请日：2017-09-06
Inventor： Chengcheng ZHANG , Mi DENG , Wei XIONG , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Junke ZHENG
IPC: C07K16/28 , C07K16/30 , A61P35/02 , A61K45/06 , A61K39/395 , G01N33/574
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61P35/02 , C07K16/3061 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C12N15/1138 , C12N2310/14 , C12N2310/531 , G01N33/57426 , G01N33/57492 , G01N2333/70503
Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
-
公开(公告)号：US20210371518A1
公开(公告)日：2021-12-02
申请号：US17275838
申请日：2019-09-12
Inventor： Zhiqiang AN , Chengcheng ZHANG , Ningyan ZHANG , Xun GUI , Mi DENG , Tao HUANG , Qiang LIU , X. Charlene LIAO
IPC: C07K16/28 , A61P35/02 , A61K45/06 , A61K39/395 , A61K47/68 , A61K51/10 , G01N33/574 , A61K47/69
Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
-
公开(公告)号：US20200079851A1
公开(公告)日：2020-03-12
申请号：US16678049
申请日：2019-11-08
Inventor： Chengcheng ZHANG , Mi DENG , Wei XIONG , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Junke ZHENG
IPC: C07K16/28 , G01N33/574 , C07K16/30 , A61K45/06 , A61K39/395 , A61P35/02 , C12N15/113
Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
-
公开(公告)号：US20170304240A1
公开(公告)日：2017-10-26
申请号：US15312790
申请日：2015-05-12
Inventor： Chengcheng ZHANG , Yi LIU , Junke ZHENG , Mi DENG , Chuo CHEN , Jiawei LIU
IPC: A61K31/194 , C12N5/078 , A61K31/155 , A61K31/20 , A61K31/197 , C12N5/0789 , A61K45/06 , C07C279/14
CPC classification number: A61K31/194 , A61K31/155 , A61K31/197 , A61K31/20 , A61K45/06 , C07C279/14 , C12N5/0634 , C12N5/0647
Abstract: The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.036 seconds)
